Oncology

Kinnate Biopharma Inc. Presents Preclinical Data on its Lead FGFR Inhibitor Candidate at the JCA-AACR Precision Cancer Medicine International Conference

09/17/2021

KIN-3248 demonstrates highly-selective, potent, and broad-spectrum activity against mutations in both the FGFR2 and FGFR3 kinase domains – including acquired gatekeeper, molecular brake, and activation loop resistance mutations Excerpt from the Press Release: SAN FRANCISCO and SAN DIEGO, Sept. 13, 2021 (GLOBE NEWSWIRE) — Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on…

Read More

Cellworks Clinical Trial Results Presented at IASLC 2021 World Conference on Lung Cancer

09/16/2021

Personalized Therapy Biosimulation Identifies Novel Biomarkers that Predict Drug and Immunotherapy Response in Patients with NSCLC Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Cellworks Group, Inc., a world leader in Personalized Medicine in the key therapeutic areas of Oncology and Immunology, today announced that results from patient stratification studies using the Cellworks Computational…

Read More

Illumina Partners with Merck to Develop and Commercialize Companion Diagnostic and Research Tests for Use in Identifying Specific Cancer Mutations

09/15/2021

Excerpt from the Press Release: SAN DIEGO, Sept. 7, 2021 /PRNewswire/ — Illumina, Inc. (NASDAQ: ILMN) and Merck (known as MSD outside the United States and Canada) today announced a partnership to develop and commercialize tests that identify genetic mutations used in the assessment of homologous recombination deficiency (HRD). Patients whose tumors are HRD-positive may be…

Read More

Researchers replicate COVID-19 infections with lab-grown ‘mini-lungs’

09/15/2021

Excerpt from the Press Release: Researchers at the University of California, San Diego (UCSD) have grown miniature human lungs in a lab dish that they say come the closest to mimicking the real thing—complete with all the myriad cell types found in the body. The small organoids of human tissue could help rapidly iterate the…

Read More

The McQuade Center for Strategic Research and Development Enters Agreement with Sentinel Oncology to Develop Breakthrough Treatment for Fragile X Syndrome

09/14/2021

Excerpt from the Press Release: RINCETON, N.J.–(BUSINESS WIRE)–The McQuade Center for Strategic Research and Development, LLC (MSRD), a member of the global Otsuka family of pharmaceutical companies, announces today that it has entered an agreement with Sentinel Oncology (Sentinel), a drug discovery company. The McQuade Center for Strategic Research and Development at Otsuka in the…

Read More

Adaptimmune Updates Data from its Phase 1 Trial for Liver Cancer at ILCA Showing Clinical Benefit

09/14/2021

Excerpt from the Press Release: One complete response, and a disease control rate of 64% with stable disease for ≥16 weeks in two patients, as of the data cutoff – – Data presented today at the International Liver Cancer Association meeting at 12:25 p.m. CET – PHILADELPHIA and OXFORDSHIRE, United Kingdom, Sept. 05, 2021 (GLOBE…

Read More

Affinia Therapeutics Announces Indications for Lead Gene Therapy Programs to Advance the Treatment of Neurologic and Neuro-oncologic Diseases supported by Multi-Year Manufacturing Agreement with Lonza Group

09/13/2021

Excerpt from the Press Release: Indications include metachromatic leukodystrophy, a rare, progressive, and fatal disease affecting the nervous system, and brain metastases secondary to HER2+ breast cancer, a common and deadly form of cancer – Affinia Therapeutics to use its proprietary technologies and capsids with improved properties to bring the promise of gene therapy to…

Read More

Largest study of its kind informs treatment of breast cancer in men

09/10/2021

Excerpt from the Press Release: Commonly used recurrence risk tests found to be useful for male patients Breast cancer is usually thought of as a disease that affects women, but many are not aware that men can develop breast cancer as well. Two-hundred and forty men in Canada were diagnosed with the disease in 2020…

Read More

Researchers uncover evolutionary forces at play in the aging of the blood system and identify people at increased risk of blood cancer

09/10/2021

Excerpt from the Press Release: Discovery could provide early warning for blood malignancies, triggering proactive screening and enabling early treatment Toronto – (August 17, 2021) As people age, mutations can build up in blood stem cells and their clones in a process known as age-related clonal hematopoiesis, or ARCH. ARCH can be a risk factor…

Read More

eFFECTOR Therapeutics Debuts as Publicly Traded Next-Generation Oncology Company Advancing Mature Pipeline with New Class of Cancer Therapies

09/07/2021

Excerpt from the Press Release: SAN DIEGO, Aug. 25, 2021 (GLOBE NEWSWIRE) — eFFECTOR Therapeutics, Inc. (eFFECTOR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today completed its business combination with Locust Walk Acquisition Corp. (NASDAQ: LWAC). The resulting combined company (the Company) has been renamed “eFFECTOR Therapeutics, Inc.” and…

Read More